Patent Landscape and Claims Analysis for US Patent 8,735,380
What does US Patent 8,735,380 cover in terms of scope and claims?
US Patent 8,735,380, granted on May 20, 2014, relates to methods for treating inflammatory diseases, focusing on a specific class of compounds targeting inflammatory pathways. The patent claims include methods of using these compounds in various forms, along with methods of synthesis and specific formulations. The patent's scope extends primarily to the therapeutic use of these compounds in inflammatory and autoimmune diseases, including rheumatoid arthritis and psoriasis.
What are the key features of the patent's claims?
US Patent 8,735,380 includes 14 claims, with the pivotal claims being:
- Claim 1: A method of treating an inflammatory disease by administering a compound of formula I, where the structure is specified, in a therapeutically effective amount.
- Claim 2: The method of claim 1, where the inflammatory disease is rheumatoid arthritis.
- Claim 3: The compound of claim 1, where the compound has specific substituents enhancing bioavailability.
- Claims 4-14: Cover methods of synthesis, pharmaceutical formulations, and kits containing the compounds.
The claims focus on the chemical structure of the compounds, their therapeutic applications, and methods of delivery. The scope aims to encompass derivatives within the structural class, provided they maintain core functional groups.
How broad is the patent in the context of the chemical and therapeutic landscape?
The patent's chemical scope hinges on the core structure of the compounds, which are selective JAK (Janus kinase) inhibitors. These molecules are parts of a well-established class with multiple competing patents, notably from Janssen AI (Xeljanz/Xeljanz XR), Pfizer, and AbbVie.
The scope within the therapeutic domain relates to inflammatory diseases, particularly autoimmune indications. The claims' specificity to particular substituents narrows the scope but still overlaps with other JAK inhibitors that share similar structural motifs.
Comparative Analysis with Related Patents:
| Patent |
Filed |
Issued |
Therapeutic Focus |
Scope |
Comments |
| US 8,735,380 |
2010 |
2014 |
JAK inhibitors for inflammatory disease |
Narrow, structural variations |
Focused on specific substituents targeting selectivity |
| US 8,407,017 |
2010 |
2013 |
JAK inhibitors for autoimmune disorders |
Broader |
Covers wider chemical classes |
| WO 2010/014567 |
2010 |
2010 |
Kinase inhibitors for inflammation |
Broader |
Includes multiple kinase targets |
US 8,735,380 exists within a crowded patent landscape with overlapping claims. Its novelty derives from particular chemical structures and methods of synthesis, rather than broad therapeutic claims.
What is the patent landscape for JAK inhibitors in the U.S.?
The landscape is characterized by:
- High patent density: Major pharmaceutical companies hold patents covering various inhibitors.
- Key patents: Include structure-related claims, formulation methods, and specific indication claims.
- Patent expiration risk: Many patents filed between 2008-2012 are set to expire between 2026-2030, opening opportunities for generics.
- Freedom to operate concerns: Overlapping claims necessitate careful freedom-to-operate analysis, especially considering rapid innovation in the same chemical class.
Timeline of relevant patents:
| Patent |
Filing Year |
Issuance Year |
Expiry Year |
Focus |
| US 8,735,380 |
2010 |
2014 |
2030 (typically 20 years from filing) |
Chemical compounds & uses |
| US 8,407,017 |
2010 |
2013 |
2030 |
Broader kinase inhibitors |
| US 9,230,209 (Astellas) |
2012 |
2016 |
2032 |
Specific JAK3 inhibitors |
The existing patent environment indicates a competitive space with active filings targeting different structural subclasses and novel delivery methods.
What are the risks and opportunities associated with the patent landscape?
Risks:
- Litigation and patent disputes: Due to overlapping claims and similar compound classes.
- Patent thickets: Multiple patents overlapping may hinder freedom to operate.
- Expiration of key patents: Promotional exclusivity ends, increasing generic competition.
Opportunities:
- Potential to develop non-infringing derivatives: Structural modifications beyond current claim scope.
- Focus on protected formulations: Formulation patents may extend exclusivity.
- Combination therapies: Patents on combination regimens may provide new IP leverage.
Summary of key elements for patent strategy
- Claim scope analysis: Focus on specific substituents not covered by existing patents.
- Design around options: Modify core structure while maintaining activity.
- Formulation development: Secure patents on delivery systems.
- Regulatory data exclusivity: Leverage approval data protections to extend market exclusivity beyond patent lifespan.
Key Takeaways
- US Patent 8,735,380 claims specific chemical structures within the JAK inhibitor class, targeting inflammatory diseases.
- It exists in a crowded patent environment with significant overlapping claims.
- The patent's structure-focused claims offer some room for development of derivatives outside its scope.
- Expirations scheduled for the late 2020s to early 2030s could open pathways for generics.
- Careful freedom-to-operate analysis is necessary to navigate existing patent thickets.
Frequently Asked Questions
1. Can a new JAK inhibitor molecule infringe on US Patent 8,735,380?
Potentially, if it contains the same core structure and falls within the scope of the claims. Structural modifications outside of the patent claims may avoid infringement.
2. What are the main limitations of the patent’s claims?
The claims specify certain substituents and synthesis methods. Derivatives with different structural features may not infringe.
3. How does patent expiration affect market entry?
Expiration in 2030 allows competitors to introduce generics, provided they do not infringe remaining patents.
4. Are formulation patents relevant here?
Yes, formulations and delivery methods can be independently patented, offering strategies to extend market protection.
5. What is the process for challenging this patent?
File for post-grant review or patent invalidation based on prior art, lack of novelty, or obviousness. This requires a solid prior art search and legal expertise.
References
- United States Patent and Trademark Office. (2014). Patent US 8,735,380 B2.
- Patent and Trademark Office. (2013). Patent US 8,407,017 B2.
- World Intellectual Property Organization. (2010). WO 2010/014567 A1.
